Imatinib has revolutionized drug therapy of chronic myeloid leukemia (CML). Preclinical
studies were promising but the results of clinical trials by far exceeded expectations …

Imatinib is a molecularly targeted therapy that inhibits the oncogenic fusion protein BCR-
ABL, the tyrosine kinase involved in the pathogenesis of chronic myelogenous leukemia …

Imatinib mesylate (STI571, Gleevec, Glivec; Novartis, Basel, Switzerland) has profoundly
changed the management of chronic myeloid leukemia (CML). The unprecedented efficacy …

The advent of the Bcr-Abl selective tyrosine kinase inhibitor imatinib mesylate (Glivec,
Gleevec, Novartis, East Hanover, NJ) has substantially changed the treatment landscape for …

Chronic myeloid leukemia (CML) is characterized by the Philadelphia translocation that
fuses BCR sequences from chromosome 22 upstream of the ABL gene on chromosome 9 …

We investigated whether increasing the dose of imatinib mesylate might overcome drug
resistance in patients with Philadelphia chromosome–positive (Ph+) chronic myelogenous …

Selective inhibition of the BCR-ABL tyrosine kinase by imatinib has substantially changed
the therapy of chronic myelogenous leukemia (CML). Despite high rates of hematologic and …

Purpose: Review the state-of-art knowledge of the biology and therapy of chronic
myelogenous leukemia (CML). Experimental Design: A review of the literature was …

Since its approval in 2001 for frontline management of chronic myelogenous leukemia
(CML), imatinib has proven to be very effective in achieving high remission rates and …

The scientists of today have become accustomed to the extremely rapid pace of progress in
the biomedical sciences spurred on by the discovery of recombinant DNA and the advent of …